CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients. (27th November 2020)

• Record Type: Journal Article
• Authors: Donadeu, Laura; Revilla-López, Eva; Jarque, Marta; Crespo, Elena; Torija, Alba; Bravo, Carles; Los Arcos, Ibai; Meneghini, Maria; Favà, Alex; Román, Antonio; Monforte, Víctor; Bestard, Oriol
• Is Part Of: Journal of infectious diseases. Volume 224:Number 3(2021)
• Page Start: 526
• Page End: 531
• Publication Date: 2020-11-27
• Subjects: lung transplantation -- CMV infection -- immune monitoring -- cellular immunity -- personalized therapy; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa727
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Monitoring cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) is useful in predicting late-onset CMV infection after solid organ transplantation, but few data have been reported after lung transplantation (LT). CMV CMI against 2 CMV antigens (IE-1, pp65) was evaluated in 60 seropositive LT at 6-month prophylaxis withdrawal. LT with late-onset CMV infection showed significantly lower (IE-1)CMV CMI than patients without ( P = .045), and was more evident in patients developing high viral loads ( P = .010). (IE-1)CMV CMI independently predicted high first late-onset viral replication (odds ratio, 4.358; 95% confidence interval, 1.043–18.215). CMV-specific CMI may be useful in CMV preventive strategies after LT.